NEOG
Neogen CorporationNeogen Corporation operates in the In Vitro & In Vivo Diagnostic Substances industry.
The numbers · FY2026, filed
SEC EDGARAll filed figures
Snapshot
SEC EDGAR · FY 2026-05-31Revenue by fiscal year
Operating leverage — margins
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $527.2M | $822.4M | $924.2M | $894.7M | $870.4M |
| Gross Profit | $243.0M | $406.0M | $463.9M | $421.4M | $408.5M |
| Operating Income | $58.6M | $37.5M | $58.6M | $-1.1B | $-21.6M |
| Net Income | $48.3M | $-22.9M | $-9.4M | $-1.1B | $-7.9M |
| Diluted EPS | $0.45 | $-0.12 | $-0.04 | $-5.03 | $-0.04 |
| Operating Cash Flow | $68.0M | $41.0M | $35.3M | $58.2M | $83.2M |
| Free Cash Flow | — | — | — | — | — |
Same industry
In the screener →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.